Claims for Patent: 12,121,509

Summary for Patent: 12,121,509

Title:	Methods of improving renal function
Abstract:	Provided herein are methods of improving kidney function in a subject in need thereof.
Inventor(s):	Philip Thomas Frohlich, Andrew James KING, Chidambaram Ramachandran, Sarah Beth Noonberg
Assignee:	Chinook Therapeutics Inc
Application Number:	US18/223,355
Patent Claims:	1. A method of treating IgA nephropathy in an IgA nephropathy-diagnosed subject, comprising administering to the subject from about 0.20 mg to about 1.5 mg of atrasentan, or an equivalent amount of a pharmaceutically acceptable salt thereof. 2. The method of claim 1, wherein the subject has IgA nephropathy as indicated by a kidney biopsy of the subject. 3. The method of claim 2, wherein the kidney biopsy further comprises detecting deposition of IgA-immune complexes in the kidney. 4. The method of claim 1, wherein the subject has IgA nephropathy as indicated by detection of galactose-deficient IgA. 5. The method of claim 1, wherein the subject has IgA nephropathy as indicated by detection of anti-glycan autoantibodies. 6. The method of claim 1, wherein the subject is administered from about 0.40 mg to about 0.85 mg of atrasentan, or an equivalent amount of a pharmaceutically acceptable salt thereof. 7. The method of claim 1, wherein the subject is administered about 0.75 mg of atrasentan, or an equivalent amount of a pharmaceutically acceptable salt thereof. 8. The method of claim 1, wherein atrasentan is administered as atrasentan mandelate. 9. The method of claim 1, wherein the subject has not been previously diagnosed with one or more of diabetic nephropathy, HIV/AIDS, or acute kidney failure. 10. A method of reducing proteinuria in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of: (i) atrasentan in an amount of from about 0.20 mg to about 1.5 mg, or an equivalent amount of a pharmaceutically acceptable salt thereof; and (ii) an angiotensin converting enzyme (ACE) inhibitor and/or (iii) an angiotensin II receptor blocker (ARB); and (iv) optionally, a diuretic; wherein the subject has biopsy-diagnosed IgA nephropathy. 11. The method of claim 10, wherein the ACE inhibitor is quinapril, fosinopril, perindopril, captopril, enalapril, enalaprilat, ramipril, cilazapril, delapril, fosenopril, zofenopril, indolapril, benazepril, lisinopril, spirapril, trandolapril, perindep, pentopril, moexipril, rescinnamine, or pivopril. 12. The method of claim 11, wherein the ACE inhibitor is lisinopril. 13. The method of claim 10, wherein the ARB is candesartan, candesartan cilexetil, eprosartan, irbesartan, losartan, olmesartan, olmesartan medoxomil, telmisartan, valsartan, azilsartan medoxomil, or BRA-657. 14. The method of claim 13, wherein the ARB is losartan or olmesartan. 15. The method of claim 10, wherein the diuretic is administered. 16. The method of claim 15, wherein the diuretic is hydrochlorothiazide, trichlormethiazide, hydroflumethiazide, quinethazone, metolazone, chlorothiazide, chlorthalidone, indapamide, methyclothiazide, bumetanide, torsemide, piretanide, ethacrynic acid, bumetanide, furosemide, triamterene, spironolactone, eplerenone, or amiloride. 17. The method of claim 16, wherein the diuretic is chlorothiazide or hydrochlorothiazide. 18. The method of claim 16, wherein the diuretic is bumetanide, torsemide, or furosemide. 19. The method of claim 10, wherein the diuretic is not administered. 20. The method of claim 10, wherein the subject is administered from about 0.40 mg to about 0.85 mg of atrasentan, or an equivalent amount of a pharmaceutically acceptable salt thereof. 21. The method of claim 10, wherein the subject is administered about 0.75 mg of atrasentan, or an equivalent amount of a pharmaceutically acceptable salt thereof. 22. The method of claim 10, wherein atrasentan is administered as atrasentan mandelate. 23. The method of claim 10, wherein the subject has not been previously diagnosed with one or more of diabetic nephropathy, HIV/AIDS, or acute kidney failure. 24. A method of treating IgA nephropathy in a subject having a brain natriuretic peptide (BNP) level of at least 200 pg/mL, comprising administering to the subject from about 0.20 mg to about 1.5 mg of atrasentan, or an equivalent amount of a pharmaceutically acceptable salt thereof. 25. The method of claim 24, wherein the subject having has a brain natriuretic peptide (BNP) level of at least 400 pg/mL. 26. The method of claim 24, wherein the subject is administered from about 0.40 mg to about 0.85 mg of atrasentan, or an equivalent amount of a pharmaceutically acceptable salt thereof. 27. The method of claim 24, wherein the subject is administered about 0.75 mg of atrasentan, or an equivalent amount of a pharmaceutically acceptable salt thereof. 28. The method of claim 24, wherein atrasentan is administered as atrasentan mandelate. 29. The method of claim 24, wherein the subject has not been previously diagnosed with one or more of diabetic nephropathy, HIV/AIDS, or acute kidney failure. 30. The method of claim 1, wherein atrasentan is administered as atrasentan hydrochloride. 31. The method of claim 1, wherein atrasentan is administered orally at a dose of about 0.75 mg of atrasentan, or an equivalent amount of a pharmaceutically acceptable salt thereof, once per day. 32. The method of claim 1, wherein the subject has been diagnosed with IgA nephropathy as a primary glomerular disease. 33. The method of claim 1, wherein the subject has not been previously diagnosed with a chronic kidney disease that is other than IgA nephropathy. 34. The method of claim 1, wherein the subject is at risk of disease progression. 35. The method of claim 1, wherein the subject is at a high risk of progression to end-stage renal disease. 36. The method of claim 1, wherein the subject has a proteinuria of at least about 1 g/day and/or an estimated glomerular filtration rate (eGFR) below 60 mL/min/1.73 m2 for at least about 3 months before first administration of atrasentan or a pharmaceutically acceptable salt thereof. 37. The method of claim 1, wherein the subject has a proteinuria of at least about 1 g/day for at least about 3 months prior to first administration of atrasentan or a pharmaceutically acceptable salt thereof. 38. The method of claim 1, wherein the subject has a proteinuria of at least about 1.5 g/day for at least about 3 months prior to first administration of atrasentan or a pharmaceutically acceptable salt thereof. 39. The method of claim 1, wherein the subject has been receiving one or more renin-angiotensin system (RAS) inhibitors for at least about 12 weeks prior to first administration of atrasentan or a pharmaceutically acceptable salt thereof. 40. The method of claim 1, wherein the subject has been receiving the maximally tolerated stable dose of one or more renin-angiotensin system (RAS) inhibitors for at least about 12 weeks prior to first administration of atrasentan or a pharmaceutically acceptable salt thereof. 41. The method of claim 40, wherein the RAS inhibitor is an ACE inhibitor, an ARB, or a combination thereof. 42. The method of claim 40, wherein the dose of the RAS inhibitor is unchanged prior to and after the administration of atrasentan. 43. The method of claim 1, wherein the method results in the subject achieving a proteinuria level below about 1.0 g/day after treatment with atrasentan or a pharmaceutically acceptable salt thereof. 44. The method of claim 1, wherein the method results in the subject achieving a decrease in proteinuria of at least about 30% relative to the subject's average proteinuria for at least 3 months prior to first administration of atrasentan or a pharmaceutically acceptable salt thereof. 45. The method of claim 44, wherein the method results in the subject achieving a decrease in proteinuria of at least about 35%. 46. The method of claim 10, wherein atrasentan is administered as atrasentan hydrochloride. 47. The method of claim 10, wherein atrasentan is administered orally at a dose of about 0.75 mg of atrasentan, or an equivalent amount of a pharmaceutically acceptable salt thereof, once per day. 48. The method of claim 10, wherein the subject has been diagnosed by kidney biopsy with IgA nephropathy as a primary glomerular disease. 49. The method of claim 10, wherein the subject has not been previously diagnosed with a chronic kidney disease that is other than IgA nephropathy. 50. The method of claim 10, wherein the subject is at risk of disease progression. 51. The method of claim 10, wherein the subject is at a high risk of progression to end-stage renal disease. 52. The method of claim 10, wherein the subject has a proteinuria of at least about 1 g/day for at least about 3 months prior to first administration of atrasentan or a pharmaceutically acceptable salt thereof. 53. The method of claim 10, wherein the subject has a proteinuria of at least about 1.5 g/day for at least about 3 months prior to first administration of atrasentan or a pharmaceutically acceptable salt thereof. 54. The method of claim 10, wherein the method results in the subject achieving a proteinuria level below about 1.0 g/day after treatment with atrasentan or a pharmaceutically acceptable salt thereof. 55. The method of claim 10, wherein the method results in the subject achieving a decrease in proteinuria of at least about 30% relative to the subject's average proteinuria for at least 3 months prior to first administration of atrasentan or a pharmaceutically acceptable salt thereof. 56. The method of claim 55, wherein the method results in the subject achieving a decrease in proteinuria of at least about 35%. 57. The method of claim 24, wherein atrasentan is administered as atrasentan hydrochloride.